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Abstract: Obesity is a chronic multifactorial disease caused by imbalance between caloric intake and energy 
expenditure. The Neuroendocrine system is one of the main factors regulating energy intake in humans. The 
Neuroendocrine system is made up of cells able to synthesize and secrete amines, peptides, growth factors and 
biological mediators, known as neurohormones, which modulate various biological functions by interacting with the 
nervous and immune system. In the central nervous system, neurosecretory elements are mainly located in the 
hypothalamus which is the anatomical site of the hunger (lateral nucleus) and satiety (ventromedial nucleus) centers; 
thus it plays a key role in chemical coding of food intake. Dopamine, Noradrenaline and Serotonin are historically 
considered key points in the regulation of feeding behavior. However, other neurohormones have been identified; these 
substances, also synthesized in peripheral tissues (especially adipose tissue and digestive tract), influence food intake. 
Some of these hormones have orexigenic activity; conversely, other substances have anorexigenic activity. A constant 
balance between orexigenic and anorexigenic neurohormones is essential to ensure a smooth feeding behavior, 
whereas a subtle and progressive disruption of neurochemical transmission is sufficient to induce hyperphagia or 
anorexia. Several factors affect the synthesis and release of neuropeptides: genetic, hormonal, psychological, 
environmental, receptorial, type of feeding and meal frequency. In the recent past some drugs, as Sibutramine and 
Rimonabant, modulating the activity of several neuroendocrine mediators (Serotonin, Noradrenaline, 
Endocannabinoids), have proven to be effective in reducing weight excess, even if they were withdrawn because of 
serious side effects. Recently, promising results in this way have been obtained with Glucagon like Peptide-1 analogs, 
showing significant efficacy in counteracting weight excess without side effects. Further knowledge developments on 
these complex neuroendocrine circuits and their hypothalamic interactions in food intake regulation could open new 
frontiers for effective pharmacological therapeutic approach to Obesity and other nutritional disorders. 
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INTRODUCTION 
Obesity is a multifactorial chronic disease which 
reduces life expectancy and greatly increases health 
care spending, as it constitutes a serious 
cardiovascular risk factor by increasing morbidity and 
mortality [1, 2]. Obesity results from a prolonged 
imbalance between caloric intake and energy 
expenditure; so that body fat mass increases if a 
deregulation of energy balance occurs [2]. Appetite and 
energy balance are regulated by several 
neurochemical circuits and the Neuroendocrine system 
(NES) is one of the main factors which regulates caloric 
intake in humans. NES is made up of cells which 
synthesize and secrete amines, peptides, growth 
factors and biological mediators, so called 
neurohormones, which modulate various biological 
functions by interacting with the nervous and immune 
system. In the central nervous system (CNS), 
neurosecretory elements are mainly located in the 
hypothalamus, which is the anatomical site of the  
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hunger and satiety centers located in the lateral area 
(LHA) and in ventromedial nucleus (VMN), 
respectively; thus the hypothalamus plays a key role in 
chemical coding of food intake. 
Most studies about the role of neuromediators in the 
control of food intake were carried out at the end of the 
last century; these studies have allowed to shed light 
on many pathogenetic aspects of Obesity and have 
provided data for developing potential drug treatments. 
In the CNS Dopamine (DA), Noradrenaline (NA) and 
Serotonin (5-HT) are historically considered key points 
in the regulation of feeding behavior. However, in the 
last years many other neurohormones were identified; 
these substances, also synthesized in peripheral 
tissues, influence food intake and energy balance [3]. 
Some of these substances have orexigenic activity; 
conversely, other substances have anorexigenic 
activity. Adipose tissue, gastrointestinal tract, and 
pancreas are the main sources of these peripheral 
signals. The peripheral control of food intake includes 
afferent vagal nerves activated by distension of the 
gastrointestinal tract and by various gut hormones 
stimulating or inhibiting food intake. In the brainstem, 
the Nucleus of tractus solitarius (NTS) receives 
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viscerosensory information and it serves as gateway 
for neural signals from the gastrointestinal tract to the 
hypothalamic centers [4]. The adipose tissue, the 
largest energy storage compartment, in the recent past 
has acquired the dignity of endocrine organ, because it 
was discovered to synthesize and release molecules, 
known as adipokines, which play endocrine, autocrine 
or paracrine roles [5].  
A constant balance between orexigenic and 
anorexigenic neurohormones is essential to ensure a 
smooth feeding behavior, whereas a subtle and 
progressive disruption of neurochemical transmission is 
sufficient to induce hyperphagia or anorexia. Several 
factors influence the synthesis and release of 
neuropeptides: genetic, hormonal, psychological, 
environmental, receptorial, type of feeding and meal 
frequency. [3] 
This work reviews the most insights about the 
complex and redundant molecular mechanisms which 
regulate food intake, focusing on the most encouraging 
perspectives for the treatment of obesity. 
HYPOTHALAMIC NEUROHORMONES MODULA- 
TING FOOD INTAKE 
Several studies have identified in the hypothalamus 
neuronal sites responsible for the synthesis and 
release of orexigenic and anorexigenic 
neurotransmitters and their receptors. These 
hypothalamic neurons are able to produce more 
neurotransmitters and they are connected by a wide 
network of neuronal pathways. This intricate brain 
network integrates and releases orexigenic and 
anorexigenic signals, resulting in a complex circuit, the 
Appetite Regulation Network, which adjusts eating 
behavior [6-8]. In addition to the VMN, site of the 
satiety center, and in addition to the LHA, the 
integration center for olfactory, visual, digestive and 
metabolic information promoting food intake, other 
hypothalamic areas, such as the paraventricular 
nucleus (PVN), dorsomedial nucleus (DMN) and 
arcuate nucleus (ARC) are charged of monitoring food 
intake. Historically, classical neurotransmitters which 
play a role in modulating eating behavior and energy 
homeostasis are Dopamine (DA), Noradrenaline (NA) 
and Serotonin (5-HT) [9].  
Several evidences have confirmed that DA release 
in specific hypothalamic regions, such as the LHA, 
encourages food intake [10-12]. In contrast, several 
experimental studies have shown the anorexigenic 
activity of 5-HT; this effect is mediated by serotonin 
receptors located in the VMN and it appears to be 
selective for carbohydrate-containing foods. Moreover, 
5-HT would responsible for reducing the amount and 
frequency of food eaten [13, 14]. The noradrenergic 
system is involved in the appetite regulation through a 
dual mechanism: the activation of 1-receptors inhibits 
food intake while the activation of presynaptic 2-
receptors causes opposite effect on nutrition [15]. A 
significant number of 1- and 2-adrenergic receptors 
were observed in the PVN and several experimental 
studies have shown that the two classes of receptors 
often act in antagonism [16,17]: NA release from 
presynaptic terminals stimulates food intake probably 
by activation of 2-receptors [18] while 1-receptor 
stimulation by agonists, such as Phenylpropanolamine 
and Amifedrina, causes a dose-dependent inhibition of 
food search; this effect is totally blocked by 
pretreatment with a1-receptor antagonists, such as 
Prazosin and Benoxathian [19]. In addition, it has been 
shown that activation of 1-adrenergic receptors in the 
VMN generates postsynaptic excitatory potentials while 
2-receptor stimulation produces inhibitory potentials. 
It's very likely that, at baseline, the anorexigenic effect 
of NA mediated by 1-receptors may be predominant 
[16, 20, 21]. 
Based on this knowledge, Researchers have 
directed their efforts towards the synthesis of drugs 
able to counteract body weight gain by reducing food 
intake. In the past years, many medications able to 
reduce appetite and food intake, by acting on 
noradrenergic and serotoninergic systems, have been 
introduced and approved by the United States Food 
and Drug Administration. However, most of them such 
as Phentermine [22], Fenfluramine and its d-isomer 
Dexfenfluramine [23], were subsequently withdrawn 
due to serious cardiovascular adverse effects. Most 
recently, Sibutramine, an inhibitor of serotonin and 
norepinephrine reuptake [24], was withdrawn on the 
same grounds. 
There are several evidences supporting the role of 
brain Histamine in food intake regulation. Histamine 
neurons, localized in the hypothalamic 
tuberomammillary nucleus (TMN), project to numerous 
brain regions. Histamine is a neurotransmitter able to 
inhibit appetite by interacting with H1- and H3-
receptors in the VMN and PVN [25-29]. Some studies 
in rats have shown that treatments increasing the 
availability of brain Histamine, or drugs which activate 
H1-receptors in the CNS, suppress food intake [30-32]; 
conversely, the treatment with H1-receptor antagonists 
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or the administration of Histidine decarboxylase 
inhibitors which decreases the brain levels of 
Histamine, increase food consumption and body weight 
[27, 33]. Experimental observations in rodents seem to 
agree that H3-receptors blockade in the hypothalamus 
is beneficial for decreasing food intake and body weight 
[34,35], whereas H3-receptor agonists enhance 
feeding in rats [36]. H3-receptor antagonists increase 
Histamine release from the hypothalamus [37] because 
H3-receptors are presynaptic autoreceptors which 
inhibit Histamine synthesis and release; moreover, they 
also inhibit other neurotransmitters which control food 
intake, such as 5-HT, DA and NA.  
More recently, many other neurohormones 
synthesized in the CNS and able to influence food 
intake, have been identified; of these, Neuropeptide Y 
(NPY) and  -Melanocyte Stimulating Hormone (-
MSH) seem to be more involved in appetite control.  
Orexigenic signals 
NPY is widespread within the CNS, where it plays 
important effects on appetite stimulation, water intake 
and mood. NPY-producing neurons are located in 
different brain areas; in particular, food intake would be 
controlled by two neuronal subpopulations: the nerve 
cells of the brainstem and the hypothalamic neurons of 
the ARC which project afferents to the DMN, PVN and 
LHA [8, 38]. NPY represents the best known orexigenic 
agent: the administration of this peptide in different 
hypothalamic areas [39] and in the fourth cerebral 
ventricle causes a strong appetite stimulation [40] and 
reduces the energy consumption [41]; furthermore, 
chronic administrations of NPY cause hyperphagia and 
obesity [42,43]. The orexigenic action of NPY seems 
linked to the activation of two receptor subtypes, Y1 
and Y5 [44]. NPY synthesis and release have a 
circadian pattern [45] and NPY release is influenced by 
5-HT which seems to play an inhibitory role on NPY 
[9,46]. Moreover, gonadal hormones, glucocorticoids, 
insulin and some cytokines have modulatory effects on 
NPY synthesis and release [47-50].  
In several studies, a 19-amino acids cyclic 
neuropeptide, the Melanin-Concentrating Hormone 
(MCH), has proven potential orexigenic effects, less 
mighty and prolonged than NPY [51,52]. However, 
there are contrasting data about the involvement of this 
hypothalamic neuropeptide in the appetite regulation 
[53], although the evidences on its orexigenic effect 
[54, 55] seem to prevail on its anorexigenic activity [56, 
57].  
Two other appetite-stimulating neuropeptides, 
Orexin-A and Orexin-B, are synthesized in the LHA 
neurons and act on two receptors, OXR1 and OXR2. 
Orexin-producing neurons project to NPY-containing 
neurons in the ARC; NPY neurons express OXR1-
receptors and receive excitatory signals. Orexins have 
lower orexigenic effects than NPY and their activity 
may be due, at least in part, to stimulation of NPY 
neurons [58, 59]. Orexin-containing neurones 
intermingle partially with histaminergic neurons in the 
posterior hypothalamus. Orexin-A perfusion into rat 
stimulates food intake [60] and this effect seems to 
involve pathways mediated by Histamine H1-receptors. 
Finally, in vitro studies have shown that Orexins inhibit 
5-HT release in the hypothalamus [61]. 
According to some evidence, endogenous 
Cannabinoids such as Anandamide and 2-
arachidonoyl-glycerol (2-AG), by interacting with their 
type-1 receptor (CB1), facilitate food intake and reduce 
energy expenditure [62]. Moreover, in mice (CB1 -/-) 
with a disrupted CB1 gene [63, 64] and in rodents 
treated with CB1 antagonists, the lack of CB1-
receptors induces anorexigenic effects [65]. CB1-
receptors are widely distributed in the hypothalamus 
and the Endocannabinoid system seems to affect the 
secretion of other peptides involved in feeding behavior 
[66, 67]. In particular, an interaction between 
Endocannabinoid system and NPY has been shown in 
rats: two CB1 agonists, CP55, 940 and Anandamide, 
are able to significantly increase NPY release in the 
hypothalamus [68]. In the recent past, the CB1 
antagonist Rimonabant has been used for drug therapy 
of obesity; unfortunately, few years later it was 
withdrawn due to uncontrollable psychiatric adverse 
effects. [69]. 
Anorexigenic Signals 
The orexigenic action of NPY is counteracted by the 
anorexigenic effect of -MSH, also known as -
Melanocortin, a peptide widely distributed in the 
hypothalamus which derives from Proopiomelanocortin 
(POMC), a 267-amino acids polypeptide hormone 
precursor [70]. Five -MSH receptor subtypes have 
been identified and only two receptors, MC3 and MC4, 
are also expressed in the hypothalamus: MC3-
receptors are located in the limbic system and ARC, 
whereas MC4-receptors are spread throughout 
hypothalamus, predominantly in the PVN and LHA [71]. 
The activation of POMC neurons, which express insulin 
and serotonin receptors, promotes -MSH secretion 
[72]. In addition, POMC neurons interact with NPY 
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system: in the ARC, axons responsible for NPY release 
project toward POMC neurons, inhibiting their activity 
by -aminobutyric acid (GABA) release, the main 
inhibitory neurotransmitter of the CNS [73]. The 
dualism between these neuropeptidic systems is also 
expressed by complete suppression of NPY orexigenic 
effect after administration of -MSH agonists [73].  
A protein able to influence the anorexigenic activity 
of -MSH is the Agouti protein, primarily identified in 
the Agouti lethal yellow (Ay/a), a murine strain which 
represents a model of genetically determined obesity 
[74]. Agouti Signaling Protein (ASP), expression of 
gene mutation, acts as an antagonist of MC4-receptor 
by increasing food intake and body weight; moreover 
this protein induces chronic hyperglycemia [75]. 
Recently, a new gene, the Agouti Related Transcript 
(ART), has been identified in the hypothalamus; it 
presents high homology to Agouti gene and encodes 
for a protein Agouti related, the Agouti Related Peptide 
(AgRP). AgRP is a potent and selective antagonist of 
MC3 and MC4 receptors [76,77] and evidences that 
neurons located in the ARC, where NPY and 
ART/AgRP are co-expressed [78], as well as evidences 
that NPY and AgRP are co-released in the PVN, 
suggest that AgRP may help to block the anorexigenic 
effect of  –MSH [9].  
In addition to -MSH, POMC also generates ß-
endorphin, an opioid peptide released from the ARC 
neurons projecting in the VMN, DMN and PVN [79,80]. 
Microinjections of ß-endorphin stimulate food intake by 
activation of μ-opioid receptors [6, 8, 81]. Other opioid 
peptides, such as Dynorphin A, Methionine-Enkephalin 
and Leucine-Enkephalin, widely secreted in the 
hypothalamus, induce food intake by activation of - 
and -receptors [6, 82-84]. The orexigenic effect of 
endogenous opioids is less sustained and pronounced 
than NPY activity [83]; anatomical studies have shown 
the existence of synapses between axon terminals of 
NPY neurons and dendrites and soma of ß-endorphin 
neurons. Therefore, it has been hypothesized that NPY 
could increase food intake directly, or by favoring ß-
endorphin release [85].  
Another neuropeptide strictly related to the 
melanocortin system for the purposes of anorexigenic 
effect is the Cocaine - and Amphetamine-Regulated 
Transcript (CART). This peptide originally takes name 
from the isolation of messenger RNA produced by 
striatal neurons of rats, after treatment with 
psychostimulant drugs, such as Cocaine and 
Amphetamine [86,]. Later studies have shown the 
fragmentation of CART in several shorter peptides in 
the hypothalamic-pituitary axis and in the adrenal 
gland. These findings lead to the hypothesis that CART 
fragments play various biological functions in the 
nervous and endocrine system [86, 87]. CART-
producing neurons were found in the hypothalamus 
and limbic system; in particular in the ARC, CART 
neurons also express POMC [88]. CART peptide is an 
important anorexigenic signal: the intraventricular 
administration of this neuropeptide inhibits food intake; 
moreover, CART completely blocks the anorexigenic 
effect of NPY [9, 88, 89].  
Corticotropin-Releasing Hormone (CRH) also exerts 
inhibitory effect on food intake [6,90,91]; this 
neuropeptide secreted by hypothalamic neurons in the 
pituitary portal circulation is known to stimulate the 
release of Adrenocorticotropin hormone (ACTH) from 
the adenohypophysis [92]. CRH-producing neurons are 
mainly located in the PVN and they project up to the 
extreme zone of the median area [93]. CRH release is 
regulated by a circadian rhythm linked to the sleep-
wake cycle and its secretory spikes are in response to 
particular stress [94]. CRH microinjections in different 
hypothalamic areas have identified the sites 
responsible for anorexigenic action of CRH, probably 
mediated by two receptor subtypes, CRH-R1 and CRH-
R2 [95]. CRH neurons interact with other neuronal 
systems involved in the appetite regulation; in fact, 
these neurons express Y5- and MC4-R-receptors in the 
hypothalamus [96, 97]. Therefore, it was suggested a 
link between CRH, NPY and melanocortin system: 
CRH acts in the PVN by inhibiting the orexigenic action 
of NPY [95]; conversely, CRH production is stimulated 
by central administration of melanocortin agonists, 
while the antagonists inhibit this effect. Some studies 
have found other peptides produced by hypothalamic 
neurons such as Urocortine, belonging to the same 
family of CRH and with a primary structure partly 
homologous [98]; this peptide has a high binding 
affinity for CHR-R1- and CHR-R2-receptors [99].  
PERIPHERAL OREXIGENIC NEUROHORMONES 
Several neurohormones, synthesized in the 
peripheral tissues, particularly in the adipose tissue and 
digestive tract, influence food intake; some of these 
substances have orexigenic activity. Ghrelin is a 28-
amino acids polypeptide which exerts a strong effect on 
growth hormone (GH) release by acting directly on the 
pituitary gland. Although Ghrelin is more expressed in 
the stomach, it is also produced in the pancreas, 
kidney, immune cells, pituitary gland and ARC [100-
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104]. In the CNS Ghrelin receptors are expressed in 
the hippocampus and pituitary gland: this distribution 
suggests a possible role of Ghrelin in the hypothalamic 
mechanisms of appetite regulation [104]. It was shown 
that Ghrelin, when centrally administered, exerts a 
potent orexigenic effect slightly lower than NPY [105]. 
An important role in the modulation of Ghrelin 
orexigenic effect seems to be done by NPY and AgRP, 
since their messenger RNAs are overexpressed in the 
hypothalamus after chronic treatment with Ghrelin 
[106,107]. The simultaneous administration, at Y1-
receptor, of NPY antagonists and Ghrelin reduces the 
orexigenic effect of the hormone: these experimental 
evidences confirm the correlation between NPY and 
Ghrelin [103,108]. In turn, Ghrelin inhibits 
melanocortinic fibers probably by stimulating neurons 
of NPY/AgRP system [109]. In addition, there is 
evidence of a functional correlation between Ghrelin 
and Endocannabinoid system: Rimonabant, a CB1-
receptor antagonist, in the hypothalamus is able to 
inhibit the orexigenic response Ghrelin administration 
[67]; thus the orexigenic effect of Ghrelin could be 
mediated by endocannabinoid release in the PVN.  
Galanin (GAL) is a 29-amino acid peptide isolated in 
the small intestine and diffusely distributed in several 
sites, including the PVN, VMN and LHA [110]; 
intraventricular or hypothalamic injections of GAL 
stimulate food intake in rats already satiated [111-113]. 
There is a close anatomical and functional correlation 
between GAL-synthesizing neurons and other 
orexigenic signals in the brain of rats; in particular, 
neurons which produce NPY are in direct 
communication with those involved in GAL synthesis, 
especially in the ARC and PVN [114]: therefore we can 
hypothesize a synergistic effect of both peptides in the 
modulation of feeding behavior [8]. However, as 
demonstrated in several studies, the orexigenic effect 
of GAL is lower and shorter (30 minutes) compared to 
NPY. In addition, GAL-synthesizing neurons establish 
synaptic connections with ß-endorphin axon terminals 
in the ARC, so as to increase ß-endorfine release; on 
the other hand, pretreatment of rats with Naloxone, an 
opioid receptor antagonist, reduces GAL-induced food 
intake [111]. 
Peptide YY (PYY) is a gut hormone, belonging to 
the pancreatic polypeptides family, present in 
bloodstream in two main forms: PYY (1-36) and PYY 
(3-36) [115, 116]. PYY (1-36) is released after meal 
from intestinal L cells and exerts several 
gastrointestinal functions: it inhibits gastric acid 
secretion, pancreatic exocrine secretion and 
gastrointestinal motility; moreover it reduces 
mesenteric circulation [117-121]. Some studies have 
shown that PYY (1-36), although in low concentrations, 
is present in the CNS of mammals and it is able to 
cross the blood/brain barrier [117-119]. In particular, 
PYY (1-36)-containing neurons are located in 
hypothalamic areas and hindbrain [120] while its 
receptors are thickly distributed in the limbic system 
and thalamic nuclei [121-123]. This peptide has high 
structural homologies with NPY and several studies 
confirm that the orexigenic effect of PYY (1-36) is 
greater than NPY [124]. Although both peptides 
implement their hyperphagic effects by binding to 
specific receptor subtypes (Y1 and Y5) with 
comparable affinity, the difference probably is a longer 
link between receptors and PYY (1-36); this prolonged 
interaction may explain its higher orexigenic action than 
NPY [122, 125]. It is likely that PYY (1-36) expresses 
orexigenic effect by activation of different nutritional 
and motivational factors. Some studies [39,126] 
confirm that PYY (1-36) stimulates appetite; it also 
increases the hedonic value of food and influences 
dietary habits by changing the way to get food. Clinical 
trials have also shown some relationship between 
bulimic behavior and PYY (1-36) [127,128]. The 
involvement of the serotoninergic, adrenergic and 
opioidergic systems [129-131] in PYY (1-36)-induced 
hyperfagic behavior is widely recognized, but limited 
data are currently available about a possible 
involvement of the histaminergic system. However it 
has been demonstrated [132] that intraventricular 
infusion of the H3-receptor antagonist Tioperamide 
causes a dose-dependent decrease of hyperfagic 
effects induced by PYY (1-36). Since H3-receptors are 
also involved in the release of other neurotransmitters 
as NA, DA and 5-HT, it is possible that Tioperamide 
reduces the orexigenic effect of PYY (1-36) by 
modulating the release of other monoamines involved 
in appetite regulation. Pharmacological targeting of the 
PYY system could represent a promising strategy to 
treat obesity in the next future. 
PERIPHERAL ANOREXIGENIC NEUROHORMONES 
The main signal originating from the adipose tissue 
is Leptin, which promotes the activation of anorexigenic 
pathways in the CNS; furthermore, Leptin stimulates 
the adrenergic system, so as to increase the energy 
expenditure. Leptin is a 167-amino acids hormone, 
encoded by ob gene, which is secreted from the 
adipocytes in amounts proportional to their number and 
size [133, 134]. Leptin is able to cross the blood/brain 
barrier and reaches the CNS via a saturable transport 
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system located in the endothelial cells [135]. The 
pulsating production of Leptin occurs according to a 
circadian rhythm, with lower concentrations in the 
morning, progressively increasing up to achieve a night 
peak [136]. Membrane receptors for Leptin are located 
in the hypothalamic nuclei and exist in different 
isoforms; the most important are the short isoform (Ob-
R), which is involved in the transport mechanisms of 
Leptin in the CNS, and the long isoform (Ob-Rb), 
responsible for the metabolic effects of Leptin and 
widely distributed in the hypothalamus [137-139]. In 
humans, in both normal weight and obese subjects, 
serum levels of this hormone are related to adipose 
mass and body weight; Leptin secretion undergoes a 
drastic drop in the fasting state and it is greatly 
stimulated in case of excessive caloric intake or 
increased body fat; indeed in obese patients circulating 
levels of Leptin are quite high [140-142]. Leptin is a key 
hormone for the maintenance of energy homeostasis 
and body weight, by which the hypothalamus detects 
the nutritional status of the organism [143]. Central and 
peripheral administration of Leptin reduces food intake 
and body weight in both normal and genetically obese 
mice (ob/ob), which are characterized by lack of this 
hormone. It seems that Leptin is not able to inhibit the 
spontaneous food intake, but rather to reduce the 
amount of food eaten during a single meal [144]. 
Several studies in animal models have revealed the 
occurrence of Leptin resistance in genetically obese 
Zucker rats (fa/fa) and in both diabetic (db/db) and 
agouti (AY/a) mice, as well as in mice lacking MC4-
receptors and in those taking high-fat foods; in these 
rodents Leptin hypersecretion was observed [145-149]. 
In many obese patients have been observed a loss of 
Leptin-induced anorexigenic effects, probably due to 
alteration of transport mechanisms of this peptide 
across the blood/brain barrier [150], or resulting from 
structural aberrations of Ob-Rb receptor, or secondary 
to changes in the mechanism of post-receptorial signal 
transduction [9, 51]. 
Leptin interacts with many other peptide systems 
involved in the hypothalamic regulation of appetite. In 
this regard, a large number of experimental evidences 
suggests an interaction between Leptin and NPY: Ob-
Rb and NPY receptors are co-expressed in the ARC 
[152]; in both normal and genetically obese (ob/ob) 
mice, subjected to fasting conditions, NPY gene 
expression is inhibited by Leptin in the ARC [153,154]; 
Leptin reduces NPY levels in the hypothalamic nuclei 
[154] and inhibits NPY-induced food intake [153].  
It has been observed that Leptin significantly 
reduces GAL and MCH gene expression; after weight 
loss there is a reduction of circulating Leptin levels and 
both appetite-stimulating and energy expenditure-
reducing responses are activated, probably by 
increasing NPY, GAL and MCH gene expression [154]. 
The localization of Ob-Rb receptors in neurons which 
produce MCH and GAL suggests that these 
neuropeptides can modulate the anorexigenic effects of 
Leptin [155]. Leptin receptors were also identified in 
Orexin-producing neurons, whereby it is possible that 
Orexins can also mediate Leptin activity [58].  
On the contrary, during weight gain has been 
observed an increase in blood Leptin levels with over 
expression of POMC [156] and CRH [154] in the PVN, 
resulting in food intake reduction. The expression of 
Leptin receptors in POMC neurons suggests that 
Leptin stimulates -MSH production [157]. The direct 
correlation between CRH and Leptin is confirmed by 
the observation that CRH antagonists inhibit the 
anorexigenic effect of the hormone; instead, central 
injections of Leptin increase CRH-mRNA synthesis and 
CRH-R2 gene expression [158]. 
The monoaminergic system could also be involved 
in the mechanisms which modulate Leptin activity; 
indeed this hormone inhibits DA and NA release from 
hypotalamic synaptosomes in rats [159]; moreover, the 
lack of DA, observed in case of hyperphagia secondary 
to Leptin deficiency, suggests a potential modulating 
action of this catecholamine on Leptin effects [10]. A 
possible role of Leptin in the modulation of 5-HT activity 
has also been evaluated: peripheral or 
intracerebroventricular administration of adipose-tissue 
hormone appears to stimulate the serotoninergic 
turnover in mice [160] while, in the frontal cortex, the 
serotoninergic transporters decrease after 
intracerebroventricular administration of Leptin [161].  
Leptin could affect the feeding behavior by 
activating Histamine-containing neurons; indeed, 
administration of Histidine decarboxylase inhibitors to 
rats decreases Leptin-induced suppression of food 
intake, so as Leptin-induced hypophagia is diminished 
in H1 receptor-deficient mice [162]. 
Finally, Leptin reduces the hypothalamic levels of 
Anandamide while the concentrations of Anandamide 
and 2-AG are increased in db/db mice or in fa/fa 
Zucker rats which have Leptin resistance [163]; 
therefore hypothalamic Endocannabinoids could be 
under inhibitory control of Leptin. 
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Insulin, the first hormone historically involved in the 
appetite control, is required to determine Leptin 
secretion by adipocytes; moreover the central action of 
Insulin reduces food intake and stimulates catabolic 
pathways, by inhibiting AgRP/NPY neurons and 
stimulating POMC/CART neurons [164]. 
Pancreatic ß-cells, in addition to insulin, also 
secrete Amylin, a 37-amino acids polypeptide which is 
stored in granules and secreted with insulin after 
nutrients intake or in response to hyperglycemia [165-
167]. Amylin influences glucose homeostasis by 
inhibiting glucagon secretion and modulating gastric 
emptying and insulin secretion [168]. Plasma Amylin 
levels increase in obese patients and in subjects with 
insulin hypersecretion [169]; conversely, hormone 
levels are low in type 1 diabetes mellitus [166]. Amylin 
exerts anorexigenic effect [170] after peripheral [171] or 
central [165] administration and crosses the blood/brain 
barrier; in the CNS it shows high affinity with different 
binding sites [172, 173]. It is not clear how Amylin plays 
a role in food intake inhibition: intraperitoneal 
administration of Amylin induces anorexigenic effects 
by dopamine D2-receptors [174] and it has been shown 
that Amylin inhibits DA release from hypothalamic 
synaptosomes [175]; in addition, chronic administration 
of Amylin leads to decreased NPY levels and increased 
CCK concentrations in the CNS [176, 177]. 
Glucagon like Peptide-1 (GLP-1) is another 
important hormone which plays a key role in 
modulating food intake; it is a potent inducer of 
glucose-dependent insulin secretion and is mainly 
synthesized in the intestinal L cells [178]. As other 
gastrointestinal peptides, GLP-1 is also localized in the 
CNS; in particular, GLP-1 is expressed in caudal 
neurons of the NTS which project to several 
hypothalamic areas, including the ARC and PVN [179]. 
Intraventricular administration of GLP-1 inhibits food 
intake in fasting rats and this effect is abolished by the 
concomitant administration of Exenedin (9-39) amide, a 
potent GLP-1 antagonist [180, 181]. The anorexigenic 
activity of GLP-1 could be mediated by NPY 
transmission; indeed, NPY-induced food intake is 
inhibited by GLP-1 and stimulated by Exenedin (9-39) 
[180, 182]. Some studies have shown that Leptin 
receptors and GLP-1 mRNA are co-expressed in the 
brainstem neurons and this observation suggests that 
GLP-1 may mediate the anorexigenic effects of Leptin 
[183, 184]. 
Histamine partially mediates the appetite 
suppression of GLP-1, because the anorexigenic effect 
is reduced by pharmacological or genetic loss of H1-
receptor function [185]. GLP-1 synthesis is regulated 
not only by a combination of neuroendocrine 
stimulating factors, but also by direct contact of 
nutrients with enteroendocrine cells; after secretion, the 
hormone is rapidly degraded in bloodstream by the 
enzyme dipeptidyl peptidase IV (DPP-4) [186]. GLP-1 
also reduces the pancreatic secretion of -glucagon 
[186] and exerts extrapancreatic effects which are 
potentially relevant for therapeutic applications [187]; 
indeed, GLP-1 inhibits gastric emptying and gastric 
acid secretion [188, 189].The main limitation to the 
therapeutic use of GLP-1 is its short half-life that is less 
than two minutes; to overcome this drawback there are 
two approaches: 1) to make use of GLP-1 synthetic 
analogs, resistant to the action of DDP-4, so as to 
prolong their stimulating effect on GLP-1 receptors; 2) 
to utilize selective DPP-4 inhibitors, able to prevent the 
degradation of endogenous GLP-1 so as to increase its 
circulating levels [190]. In several studies two GLP-1 
receptor agonists, Exenatide and Liraglutide, have 
shown to inhibit appetite and reduce food intake 
without affecting energy expenditure, obtaining weight 
loss in prolonged treatments [191]. This result seems 
particularly evident using GLP-1 analogs in 
combination with metformin, suggesting a possible 
positive interaction of drugs [192]. Open-label 
extensions of double-blind clinical trials show that the 
weight reduction proceeds, without plateau, up to three 
years of treatment [193]. Then, it seems that GLP-1 
analogs, unlike other drugs which reduce body weight, 
do not induce tolerance to their weight effects, at least 
in medium term. Unlike GLP-1 analogs, DPP-4 
inhibitors do not determine weight loss nor modify body 
weight [192]. These findings indicate that GLP-1 
analogs might become an interesting therapeutic option 
in obese patients [191].  
The enzyme DPP-4, acting on gastrointestinal 
peptide YY (1-36), produces the fragment (3-36) by 
loss of N-terminal dipeptide Tyr-Pro. The fragment (3-
36) of the peptide YY, belonging to the pancreatic 
polypeptides family, has an high sequential homology 
with NPY and mediates its endogenous effects by a 
greater selectivity for Y2 inhibitory autoreceptors, 
widely expressed on NPY/AgRP neurons of the ARC 
[109,194,195]. Peptide YY and its fragment (3-36) have 
opposing effects in the regulation of feeding behavior; 
indeed, peptide YY (3-36) shows anorexigenic effects 
when it is released into the bloodstream in response to 
food intake. Plasma levels of Peptide YY (3-36), rather 
low before meals, grow up after food ingestion until 
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they reach a peak within 90 minutes and remain 
elevated for many hours. Since the peak plasma level 
is proportional to the caloric intake, this peptidic 
fragment is an important signal interconnecting gut and 
brain circuits which regulate food intake [195]. 
Peripheral infusions of this peptide induce a sensible 
appetite reduction in rats and humans; experimental 
studies on humans have shown that administration of 
peptide YY (3-36), in normal postprandial 
concentrations, significantly decreases appetite and 
reduces food intake at least 24 hours [194-196]. 
Therefore, chronic administration can lead to significant 
weight loss; thus peptide YY (3-36) could be a valuable 
therapeutic approach in the obesity treatment. Some 
studies have assessed whether obese individuals 
have, as to Leptin, a resistance to peptide YY (3-36): in 
contrast to Leptin, the results have not shown 
resistance to the anorexigenic effects of peptide YY (3-
36) in obese subjects; on the contrary, the levels of this 
peptidic fragment were minimal and this result has 
suggested that the deficiency of this peptide may 
contribute to the pathogenesis of obesity [196]. Finally, 
studies in rats suggest that peptide YY (3-36) and 
Ghrelin act in opposition in food intake regulation by 
indicating "positive" and "negative" energy states, 
respectively. The opposing action Ghrelin-Peptide YY 
(3-36) seems to be at the root of the therapeutic 
success resulting from gastric and intestinal by-pass; 
indeed, patients undergoing this type of bariatric 
surgery, before the meals have a reduction in 
circulating Ghrelin levels and a significant increase in 
plasma levels of Peptide YY (3-36) [197-198]. This 
effect leads to a continuous reduction in the compulsive 
behavior toward food, with subsequent weight loss 
already detectable a few days after the surgery [199]. 
Oxyntomodulin (OXM) is another hormone released 
from enteroendocrine L-cells after digestion, which 
induces satiety by acting via GLP-1 receptors in the 
ARC. Circulating levels of OXM are elevated in several 
conditions associated with anorexia; central injections 
of OXM reduce food intake and body weight in rodents 
suggesting that OXM sends signals about food 
ingestion to the hypothalamic appetite-regulating 
circuits. OXM administration in animals and humans 
causes weight loss by reducing food intake in 
combination with increasing energy expenditure. Thus, 
the development of long-acting analogs of OXM is an 
exciting new therapeutic avenue for addressing the 
global obesity epidemic [200-202]  
Recently, it has been demonstrated that 
Preproghrelin may undergo an additional proteolytic 
cleavage, generating a 23-amino acid peptide named 
Obestatin. Unlike Ghrelin, Obestatin has anorexigenic 
effects and reduces gastric emptying and jejunal 
contractions, counteracting weight gain; however, 
some studies have not reproduced these results 
[203,204]. It has been reported that Obestatin is unable 
to cross the blood–brain barrier and is rapidly degraded 
in bloodstream [205]. An alternative hypothesis is that 
Obestatin exerts its effects on eating through direct 
interactions with the gastrointestinal system, by 
suppressing the gastric emptying and reducing the 
contractile activity of muscle strips in jejunum. Thus, 
the inhibition of jejunal contraction could generate an 
afferent vagal signal to induce satiety in the brain. 
[206].  
Finally, the brain-gut peptide Cholecystokinin (CCK) 
might play a role in the control of food intake. CCK is 
secreted from I-cells of the small intestine and acts as 
an endogenous signal of postprandial satiety. 
Peripheral administration of CCK reduces food intake 
in humans and animal models [207-209]. Feeding 
inhibitory actions of the hormone are mediated by 
interaction with CCK receptors expressed in the 
brainstem and hypothalamus [210]. It has also been 
reported that Ghrelin attenuates the effect of CCK on 
appetite while Leptin synergistically enhances CCK 
activity [211]. 
CONCLUSION 
Food intake is regulated by a complex system of 
central and peripheral signals which interact in order to 
modulate the individual response to nutrients. The 
peripheral regulation includes signals generated in the 
adipose tissue and gastrointestinal tract while central 
control is implemented by neuroendocrine mediators in 
the hypothalamus, the integration center of several 
nutrient signals.  
The main circulating signal originating from the 
adipose tissue is Leptin, which promotes the activation 
of anorexigenic pathways in the CNS. Gastrointestinal 
tract and pancreas also contribute with several 
circulating peptides, as Ghrelin, GAL, PYY, Insulin, 
Amylin, GLP-1, Oxyntomodulin and CCK that variously 
influence food intake by acting on hypothalamic 
neurons directly, after crossing the blood–brain barrier. 
Other gastrointestinal signals reach the NTS, in the 
caudal brainstem, through the vagus nerve. From NTS 
afferent fibers project to the ARC, where these 
afferences are integrated with adiposity signals and 
hypothalamic inputs, making a complex network of 
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neuroendocrine circuits which finally elaborate the 
individual response to meal.  
The ARC contains two major populations of neurons 
controlling appetite with opposing effects on food 
intake: a subset of neurons co-expressing NPY and 
AgRP which increase food intake, and another 
subpopulation co-expressing POMC, -MSH and 
CART which inhibit food intake. Axons of these 
neurons project to “second-order” neurons located in 
hypothalamic areas, downstream the ARC, also 
involved in the control of food intake: the PVN is the 
site where anorexigenic peptides, as CRH, are 
secreted while the LHA is the area where orexant 
molecules, as MCH, are produced.  
The balance between the activities of these 
complex and integrated neuroendocrine circuits is 
critical to regulate food intake and control body weight. 
In the past years, some drugs modulating the 
activity of several central neuroendocrine mediators 
have proven effective in reducing weight excess, even 
if they were withdrawn because of their serious 
adverse effects. Recently, promising results in this way 
have been obtained with analogs of a peripheral 
mediator, GLP-1, showing significant efficacy in 
counteracting weight excess without side effects.  
The knowledge about NES is continuously evolving 
and, at the time, we probably can see just the tip of an 
iceberg. Better understanding of these systems could 
help to clarify uncertain pathogenetic aspects of the 
weight gain. Moreover, further knowledge development 
on these complex neuroendocrine circuits and their 
hypothalamic interactions in the regulation of food 
intake could open new frontiers for effective 
pharmacological therapeutic approaches to Obesity 
and other nutritional disorders. 
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